ACRO Names Chair-Elect
The Association of Clinical Research Organizations (ACRO) recently announced the election of Dr. Derek Winstanly as Chair-Elect of the association.
Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
WASHINGTON, July 10 /PRNewswire-USNewswire/ –- The Association of Clinical Research Organizations (ACRO), which represents the clinical outsourcing industry to regulators, biopharmaceutical clients, policy makers and the public in the U.S. and worldwide, recently announced the election of Dr. Derek Winstanly as Chair-Elect of the association.
Derek Winstanly, MBChB, Executive Vice President of Strategic Business Partnerships for Quintiles Transnational, was appointed the 2008 Chair-Elect in June. Dr. Winstanly is a respected leader of the clinical research organization (CRO) industry, having held various global leadership positions within Quintiles since joining the company in 1999. In his current role, he works with senior biopharmaceutical executives to provide long-term strategic solutions, and is responsible for the Office of the Chief Medical Officer as well as the ethics and quality assurance functions of the company.
“I congratulate Dr. Winstanly on his appointment as Chair-Elect of ACRO,” said David Spaight, ACRO Chair and President of MDS Pharma Services. “His experience and insight will enhance the association’s efforts to demonstrate the important contributions that CROs make to the clinical research enterprise.”
“I am pleased to join the leadership of ACRO at a time of extraordinary growth for our industry,” added Dr. Winstanly. “I look forward to driving the association’s efforts to increase public understanding about the vital role CROs play in the conduct of safe and high-quality clinical studies to accelerate the development of new medical treatments.”
About ACRO
The Association of Clinical Research Organizations (ACRO) is the professional organization of companies whose focus is clinical research. The association provides an active voice for the CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. ACRO helps its members improve the quality, efficiency and safety of biomedical research. For more information, please visit www.acrohealth.org <http://www.acrohealth.org/> .
CONTACT: Courtney Gray Haupt of Association of Clinical Research Organizations, +1-202 543 4018, [email protected]
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
